AS1069562 | CAS#1214994-13-4 | 5-HT inhibitor

MedKoo Cat#: 563154 | Name: AS1069562

Description:

WARNING: This product is for research use only, not for human or veterinary use.

AS1069562 is an inhibitor of serotonin (5-HT) and norepinephrine (NE) reuptake. It acts by significantly restoring decreased insulin-like growth factor 1 and fibroblast growth factor 2 mRNA levels in dorsal root ganglion and spinal cord, respectively.

Chemical Structure

AS1069562

CAS#1214994-13-4

Theoretical Analysis

MedKoo Cat#: 563154

Name: AS1069562

CAS#: 1214994-13-4

Chemical Formula: C20H23NO5S

Exact Mass:

Molecular Weight: 389.46

Elemental Analysis: C, 61.68; H, 5.95; N, 3.60; O, 20.54; S, 8.23

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

AS1069562; AS-1069562; AS 1069562;

IUPAC/Chemical Name

(S)-2-(((1H-inden-7-yl)oxy)methyl)morpholine benzenesulfonate

InChi Key

HLSBLOLRAXOIFW-YDALLXLXSA-N

InChi Code

InChI=1S/C14H17NO2.C6H6O3S/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12;7-10(8,9)6-4-2-1-3-5-6/h1-4,6,12,15H,5,7-10H2;1-5H,(H,7,8,9)/t12-;/m0./s1

SMILES Code

O=S(C1=CC=CC=C1)(O)=O.C2(C=CC3)=C3C(OC[C@H]4OCCNC4)=CC=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 389.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Murai N, Fushiki H, Honda S, Murakami Y, Iwashita A, Irie M, Tamura S, Nagakura Y, Aoki T. Relationship between serotonin transporter occupancies and analgesic effects of AS1069562, the (+)-isomer of indeloxazine, and duloxetine in reserpine-induced myalgia rats. Neuroscience. 2015 Mar 19;289:262-9. doi: 10.1016/j.neuroscience.2014.12.065. Epub 2015 Jan 13. PubMed PMID: 25595980. 2: Murai N, Takeshita N, Nishigaki F, Irie M, Tamura S, Aoki T, Matsuoka N. AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in rat models of nociceptive pain. Neurol Res. 2015 Jun;37(6):525-30. doi: 10.1179/1743132815Y.0000000007. Epub 2015 Jan 16. PubMed PMID: 25591424. 3: Murai N, Tsukamoto M, Tamura S, Aoki T, Matsuoka N. Antinociceptive effects of AS1069562, the (+)-isomer of indeloxazine, on spinal hypersensitivity induced by intrathecal injection of prostaglandin in mice: comparison with duloxetine and amitriptyline. Eur J Pharmacol. 2014 Jun 15;733:54-61. doi: 10.1016/j.ejphar.2014.03.038. Epub 2014 Apr 1. PubMed PMID: 24704374. 4: Murai N, Aoki T, Tamura S, Sekizawa T, Kakimoto S, Tsukamoto M, Oe T, Enomoto R, Hamakawa N, Matsuoka N. AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in a rat model of neuropathic pain with unique characteristics in spinal monoamine turnover. J Pharmacol Exp Ther. 2014 Mar;348(3):372-82. doi: 10.1124/jpet.113.208686. Epub 2013 Dec 12. PubMed PMID: 24338505. 5: Murai N, Aoki T, Tamura S, Yamamoto H, Hamakawa N, Matsuoka N. AS1069562, the (+)-isomer of indeloxazine, but not duloxetine has a curative-like analgesic effect in a rat model of streptozotocin-induced diabetic neuropathy. Neuropharmacology. 2014 Apr;79:10-6. doi: 10.1016/j.neuropharm.2013.10.030. Epub 2013 Nov 6. PubMed PMID: 24211301. 6: Ogasawara T, Itoh Y, Tamura M, Mushiroi T, Ukai Y, Kise M, Kimura K. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer. Pharmacol Biochem Behav. 1999 Sep;64(1):41-52. PubMed PMID: 10494996. 7: Yamaguchi T, Ohyama M, Suzuki M, Ozawa Y, Hatanaka K, Hidaka K, Yamamoto M. Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride. Neuropharmacology. 1998 Sep;37(9):1169-76. PubMed PMID: 9833647. 8: Sugao H, Yamazaki S, Shiozawa H, Yano K. Taste masking of bitter drug powder without loss of bioavailability by heat treatment of wax-coated microparticles. J Pharm Sci. 1998 Jan;87(1):96-100. PubMed PMID: 9452976. 9: Yamaguchi T, Suzuki M, Yamamoto M. Facilitation of acetylcholine release in rat frontal cortex by indeloxazine hydrochloride: involvement of endogenous serotonin and 5-HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):712-20. PubMed PMID: 9453456. 10: Nakagawa T, Ukai K, Ohyama T, Gomita Y, Okamura H. Effects of dopaminergic agents on reversal of reserpine-induced impairment in conditioned avoidance response in rats. Pharmacol Biochem Behav. 1997 Dec;58(4):829-36. PubMed PMID: 9408183. 11: Kato M, Iwata H, Katayama T, Asai H, Narita H, Endo T. Possible therapeutic effect of T-794, a novel reversible inhibitor of monoamine oxidase-A, on post-stroke emotional disturbances, assessed in animal models of depression. Biol Pharm Bull. 1997 Apr;20(4):349-53. PubMed PMID: 9145208. 12: Kimura K, Ezoe K, Yokozeki H, Katayama I, Nishioka K. A case of eosinophilic pustular folliculitis (Ofuji's disease) induced by patch and challenge tests with indeloxazine hydrochloride. J Dermatol. 1996 Jul;23(7):479-83. PubMed PMID: 8772029. 13: Yamaguchi T, Ozawa Y, Suzuki M, Yamamoto M, Nakamura T, Yamaura A. Indeloxazine hydrochloride improves impairment of passive avoidance performance after fluid percussion brain injury in rats. Neuropharmacology. 1996 Mar;35(3):329-36. PubMed PMID: 8783208. 14: Sato Y, Suzuki N, Horita H, Wada H, Shibuya A, Adachi H, Tsukamoto T, Kumamoto Y, Yamamoto M. Effects of long-term psychological stress on sexual behavior and brain catecholamine levels. J Androl. 1996 Mar-Apr;17(2):83-90. PubMed PMID: 8723430. 15: Ono S, Yamafuji T, Chaki H, Todo Y, Maekawa M, Kitamura K, Kimura T, Nakada Y, Mozumi K, Narita H. A new cognition-enhancing agent, (R)-(-)-1-(benzo[b]thiophen-5-yl)- 2-[2-(N,N-diethylamino)ethoxy]ethanol hydrochloride. Effects on memory impairment in rats generated by cerebral embolization and basal forebrain lesions. Biol Pharm Bull. 1995 Dec;18(12):1779-83. PubMed PMID: 8787808. 16: Ono S, Yamafuji T, Chaki H, Todo Y, Maekawa M, Kitamura K, Tai M, Narita H. Studies on cognitive enhancing agents. I. Antiamnestic and antihypoxic activities of 2-dimethylaminoethyl ethers and related compounds. Chem Pharm Bull (Tokyo). 1995 Sep;43(9):1483-7. PubMed PMID: 7586070. 17: Horita H, Kumamoto Y, Satoh Y, Suzuki N, Wada H, Shibuya A, Adachi H, Kurohata T, Tsukamoto T. [The preventive effect of indeloxazine hydrochloride to the sexual dysfunction caused by anti-androgenergic agent (allylestrenol)]. Nihon Hinyokika Gakkai Zasshi. 1995 May;86(5):1044-50. Japanese. PubMed PMID: 7541089. 18: Minami M, Arai H, Takahashi T, Kimura M, Noguchi I, Suzuki T, Inoue R. A preliminary study on plasma concentrations of bifemelane, indeloxazine and propentofylline in aged patients with organic brain disorders. Prog Neuropsychopharmacol Biol Psychiatry. 1995 Jan;19(1):59-64. PubMed PMID: 7708932. 19: Yamamoto M, Takahashi K, Ohyama M, Sasamata M, Yatsugi S, Okada M, Endoh H. Possible involvement of central cholinergic system in ameliorating effects of indeloxazine, a cerebral activator, on disturbance of learning behavior in rats. Prog Neuropsychopharmacol Biol Psychiatry. 1994 May;18(3):603-13. PubMed PMID: 8078992. 20: Otomo E. [Cerebral circulatory improvers and metabolic activators]. No To Shinkei. 1994 Mar;46(3):239-44. Review. Japanese. PubMed PMID: 8192938.